PD-1 Non-Small Cell Lung Cancer Market 2026 projected to hit $41.45 billion by 2030
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Evolve From 2026 To 2030?
The market for programmed death (pd)-1 non-small cell lung cancer therapies has experienced robust expansion over recent years. This market is projected to expand from $27.5 billion in 2025 to reach $29.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this historical growth include the initial limited approval of PD-1 inhibitors for NSCLC, the rising incidence of lung cancer, heightened physician understanding of immune checkpoint therapies, the historical reliance on chemotherapy as standard treatment, and the promising early clinical trial outcomes for pembrolizumab and nivolumab.
The market for programmed death (pd)-1 non-small cell lung cancer is projected to experience robust expansion in the coming years. This market is anticipated to reach a valuation of $41.45 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth during the forecast period include the introduction of innovative combination therapies, the broader application of personalized treatments guided by biomarkers, the increased uptake of mRNA vaccine-based therapeutic approaches, greater investment in immuno-oncology research, and an increase in both government and private funding directed towards cancer immunotherapy. Key trends foreseen over the forecast period encompass a greater reliance on pd-1 monotherapy for nsclc, an increase in combination treatments incorporating chemotherapy, CTLA-4 inhibitors, and VEGF inhibitors, a surge in investment dedicated to targeted therapy and mRNA vaccine research, the broadening of first-line and second-line treatment choices, and the incorporation of personalized medicine with biomarker testing into treatment strategy.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
The programmed death (PD)-1 non-small cell lung cancer market is anticipated to expand due to the rising embrace of personalized treatments. These medical approaches are customized to an individual’s genetic profile, lifestyle, and specific disease characteristics, aiming for more effective and targeted outcomes. The growing availability of genomic profiling and biomarker testing is fueling this demand, as these technologies enable the identification of specific mutations and biological indicators, thereby assisting clinicians in choosing the most effective therapies for individual patients. Specifically for programmed death (PD)-1 non-small cell lung cancer (NSCLC), personalized treatments aid by adapting therapies according to a patient’s genetic profile, tumor attributes, and immune system response. For instance, in February 2024, data from the US-based non-profit Personalized Medicine Coalition revealed that the US Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for rare diseases in 2023, a significant rise from 6 in 2022. Consequently, the increased adoption of personalized treatments is a key factor propelling the expansion of the programmed death (PD)-1 non-small cell lung cancer market.
Which Segment Areas Are Covered In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Analysis?
The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –
1) By Drug Type: Monotherapy, Combination Therapy
2) By Line of Therapy: First-line Treatment, Second-line And Beyond
3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types
What Key Developments And Trends Are Impacting The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
Major companies operating within the programmed death (PD)-1 non-small cell lung cancer market are concentrating on conducting clinical trials for innovative therapies, including monotherapy, to enhance patient outcomes. Monotherapy is a treatment approach that employs a single drug or therapy to address a disease or medical condition. For instance, in March 2025, Akeso, Inc., a biopharmaceutical company headquartered in China, announced positive results from its Phase III HARMONi-2 trial, which assessed Ivonescimab (AK112) combined with chemotherapy for the initial treatment of advanced non-small cell lung cancer (NSCLC). The study achieved its primary endpoint by significantly extending progression-free survival compared to pembrolizumab, thereby highlighting the therapeutic potential of this dual-targeted bispecific antibody.
Which Global Companies Are Actively Competing In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.
Read the full programmed death (pd)-1 non-small cell lung cancer market report here:
What Are The Leading Geographic Regions In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25888&type=smp
Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2026, By The Business Research Company
Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Market Report 2026
Non Small Cell Lung Cancer Nsclc Market Report 2026
Small Cell Lung Cancer Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
